文拉法辛与帕罗西汀对Wilson病患者焦虑情绪的干预研究  

Intervention study of venlafaxine and paroxetine in WD patients

作　　者：董婷[1] 杨文明[1] 汪瀚[1] 鲍远程[1] 黄鹏[1] 

机构地区：[1]安徽中医学院第一附属医院神经内科,安徽合肥230031

出　　处：《安徽医药》2013年第4期630-631,共2页Anhui Medical and Pharmaceutical Journal

基　　金：国家自然科学基金(No 30973748)

摘　　要：目的探讨文拉法辛与帕罗西汀对Wilson病患者焦虑情绪的疗效及安全性。方法选取合并焦虑情绪的60名Wilson病患者分别给予文拉法辛和帕罗西汀治疗8周。于治疗前后分别采用汉密尔顿焦虑量表(HAMA),及治疗中出现的症状量表(TESS)评定疗效和不良反应。结果文法拉辛组显效率为80%,有效率为93.33%,帕罗西汀组显效率为73.33%,有效率86.67%。两组疗效相仿。在治疗2周末时,文法拉辛组减分多于帕罗西汀,差异有显著性。两组不良反应均轻微。结论在药物驱铜治疗的同时,还要重视心理治疗,这样可以提高患者临床疗效;文拉法辛和帕罗西汀是较好的抗焦虑药物。Objective To observe the efficacy and the safety of venlafaxine and paroxetine in WD patients. Methods 60 WD patients suffering from obvious anxiety were given venlafaxine and paroxetine respectively for 8 weeks. HAMA and TESS were adopted to evaluate the efficacy and side effects before and after the treatment. Results In venlafaxine group, the effect rate was 80% and total effective rate was 93.33%. In paroxetine group,the effect rate was 73.33% and total effective rate was 86.67%. The effect of the two groups were a- like. The decreased score rate in venlafaxine group was higher than that in paroxetine group after 2 weeks＇ treatment, and the difference was significant. The adverse effects of the two groups were slight. Conclusion WD patients have many psychological symptoms. In addi- tion to pharmaceutical therapy for removing copper, psychotherapy should be emphasized in WD patients to improve clinical efficacy. Ven- lafaxine and paroxetine have good clinical effects and slight adverse effects in the treatment of anxiety disorder.

关 键 词：WILSON病 文拉法辛 帕罗西汀 

分 类 号：R742.4[医药卫生—神经病学与精神病学]